Catalyst
Slingshot members are tracking this event:
Novartis (NVS) receives first ever FDA approval for a CAR-T cell therapy, Kymriah (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| NVS |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 30, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Car-t Cell Therapy, Kymriah, Ctl019, B-cell All
